Amneal to launch $225 million add-on term loan on Thursday morning

By Sara Rosenberg

New York, May 11 – Amneal Pharmaceuticals LLC is scheduled to hold a lender call at 11 a.m. ET on Thursday to launch a fungible $225 million add-on term loan B due November 2019, according to a market source.

J.P. Morgan Securities LLC is the lead bank on the deal.

Pricing on the add-on term loan matches existing term loan pricing at Libor plus 350 basis points with a 1% Libor floor.

The add-on is being offered with an original issue discount of 99.266 and has 101 soft call protection for six months, the source said.

Proceeds will be used to fund a dividend and for general corporate purposes.

In connection with the add-on term loan, the company is seeking an amendment to its existing credit facility, for which lenders are offered a 25 bps amendment fee, the source added.

Amneal Pharmaceuticals is a Bridgewater, N.J.-based manufacturer of generic pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.